Epigenomics, Myriad to Hunt DNA Methylation Markers for Cancer Drug Response | GenomeWeb
NEW YORK (GenomeWeb News) - Epigenomics today said it will collaborate with Myriad Genetics to identify DNA methylation biomarkers that may predict patient response to a cancer drug.
 
Under the collaboration, Epigenomics will use its Differential Methylation Hybridization microarray platform for genome-wide profiling of samples provided by Myriad. The company hopes to discover methylation biomarkers that are linked to sensitivity and resistance to the undisclosed marketed oncology drug.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.